Company newsCompany release

Blackstone BX

Blackstone to provide $750 million to Johnson & Johnson for drug development

The funds support Phase 3 clinical development of OLN324, an investigational therapy for serious retinal vascular diseases.

GetSignal 

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Blackstone said funds managed by Blackstone Life Sciences will provide $750 million in development funding to Johnson & Johnson, announced November 16, 2026.

Key facts

Amount
$750 million
Recipient
Johnson & Johnson
Program
OLN324, Phase 3 clinical development
Announced
November 16, 2026

All BX news

Source: The company's release on Business Wire, November 16, 2026.

Written by GetSignal with AI from the company's press release. How we make news

Not investment advice.

More company news

Blackstone first, then the newest
  1. Blackstone subsidiary prices $1.1 billion senior notes offering

    BX · Blackstone · Form 8-K and release · Oct 27, 2026

  2. AMD completes acquisition of World Labs

    AMD · Advanced Micro Devices · Company release · Nov 16, 2026

All company news